TATAA Biocenter expands its bioanalytical services with HTG certification
TATAA Biocenter, a leading provider of high-quality molecular analysis services, announced today that it has become a certified Qualified Service Provider for HTG Molecular Diagnostics. This certification will enable TATAA to offer high-throughput, multiplex gene expression profiling to its customers, and expand its portfolio of molecular analysis services.
HTG Molecular Diagnostics is a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, HTG EdgeSeq™. This highly sensitive and specific method for analyzing gene expression enables researchers to study large numbers of genes simultaneously.
This technology is specifically useful for research applications that require the analysis of complex gene expression profiles, such as oncology, immunology, and neurology research. Unlike RNA-Seq, the HTG EdgeSeq technology does not require RNA extraction, and can use small amounts of tissue material, typically several mm2, to generate reproducible gene expression profiles.
“Your commitment to excellence and dedication to providing a top-notch service has been truly inspiring and we are thrilled to have you as a partner” said Selina Gaertner, Director, EU Medical Affairs, HTG Molecular Diagnostics.
“We are really pleased to count TATAA Biocenter among our limited number of Qualified Service Providers. They represent the perfect service we need to recommend to our end users, running our technology with high standards and professionalism” stated Jean Claude Gerard Vice President, Global Sales, HTG Molecular Diagnostics.
“This certification reflects our commitment to providing our customers with the most advanced genomic services available. With HTG EdgeSeq technology, we can now offer even more comprehensive solutions for gene expression profiling and biomarker discovery.” added Jens Björkman, COO, TATAA Biocenter.
TATAA Biocenter is a pioneer in qPCR, digital PCR, and Next-Generation Sequencing (NGS) services and products, serving customers in academia, industry, and healthcare. With this certification, TATAA Biocenter continues to expand its portfolio of advanced molecular biology technologies, providing its clients with the most innovative and reliable solutions for their research and clinical needs.
Contact for more info:
Martin Cooke, TATAA Biocenter, Marketing & Comms Specialist.
Emaii: martin.cooke@tatta.com
ABOUT TATAA BIOCENTER
TATAA Biocenter is a leading provider of molecular services to the Advanced Therapies and Medical products (ATMP) industry in Europe and to the Cell and Gene Therapy industry in the United States. With ISO 17025 accreditation and Good Laboratory and Clinical Practices (GLP/GCP) ready facility TATAA is perfectly positioned to support the pharmaceutical industry with biomarker profiling, including genomics, transcriptomics, and proteomics with traditional qPCR, dPCR, and NGS methods, as well as proprietary methods.
ABOUT HTG:
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.
